NCT00441987

Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953

A Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-953 Administered Orally to Healthy Japanese Male Subjects and Healthy Elderly Male Japanese Subjects.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 96 (actual)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: Male
• Age: 20 Years – 120 Years
• Healthy volunteers: Accepted

Summary

The purpose of the protocol is to assess the initial pharmacokinetic (PK) profile of a single oral dose of GSI-953 to healthy male Japanese subjects and healthy elderly male Japanese subjects.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	GSI-953

Timeline

• Start date: 2007-02-01
• Primary completion: 2009-07-01
• Completion: 2009-07-01
• First posted: 2007-03-01
• Last updated: 2022-05-03

Locations

1 site across 1 country: Japan